Discounted Cash Flow
Agomab Therapeutics N.V. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $406.0k | $-11.6m | $-12.5m | -2853.7% | $-2.82 |
| 2017 | $249.0k (-38.7%) | $-10.9m (6.2%) | $-11.4m (8.4%) | -4365.1% (-53.0%) | $-2.28 (19.1%) |
| 2018 | $119.0k (-52.2%) | $-6.3m (41.6%) | $-8.8m (23.1%) | -5331.1% (-22.1%) | $-12.48 (-447.4%) |
| 2019 | — | $-10.6m (-66.6%) | $-6.7m (23.7%) | — | $-17.86 (-43.1%) |
| 2020 | — | $-12.8m (-20.8%) | — | — | $-0.17 (99.0%) |
| 2021 | $15.2m | $12.5m (197.8%) | $-9.3m | 82.2% | $-0.07 (58.1%) |
| 2022 | $25.0k (-99.8%) | $27.6m (121.6%) | $-22.8m (-144.2%) | 110584.0% (134456.6%) | $-0.19 (-163.7%) |
| 2023 | $210.0k (740.0%) | $24.2m (-12.4%) | $-24.6m (-7.7%) | 11533.8% (-89.6%) | $-35.63 (-18771.8%) |
| 2024 | $2.3m (999.0%) | $13.9m (-42.4%) | $-46.8m (-90.4%) | 604.2% (-94.8%) | $-107.09 (-200.6%) |
| 2025 | $1.5m (-33.0%) | $9.0m (-35.5%) | $-51.7m (-10.5%) | 581.8% (-3.7%) | $-143.22 (-33.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.